KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Debt Repayments (2020 - 2021)

AbCellera Biologics (ABCL) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $107000.0 as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Long-Term Debt Repayments rose 272.58% year-over-year to $107000.0, compared with a TTM value of $1.8 million through Dec 2021, down 90.86%, and an annual FY2021 reading of $1.8 million, down 90.86% over the prior year.
  • Long-Term Debt Repayments was $107000.0 for Q2 2021 at AbCellera Biologics, down from $1.7 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $15.0 million in Q3 2020 and bottomed at -$62000.0 in Q2 2020.